Data from Pharmawand - Curated by Toby Galbraith - Date added 07 August 2017

The National Institute for Health and Care Excellence (NICE) in preliminary guidance has decided that Keytruda ( pembrolizumab) from Merck Inc., is not cost effective as a treatment for Urothelial (Bladder) Cancer. NICE accepted that the drug significantly improved overall survival (extension of lives by more than three months) compared to docetexel and paclitaxel chemotherapy but its cost effectiveness is uncertain as its economic modelling is unclear. A final determination will be made in November.

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Breakthrough Cancer Pain Learning Zone

Invitation to watch the online broadcast of the BeCOn OWN event 'Shifting paradigms in BTcP management' on June 16 2017.

Visit Breakthrough Cancer Pain Learning Zone

Transplantation

See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Visit Transplantation

Related Content